Drug Discovery Chemistry
Total Page:16
File Type:pdf, Size:1020Kb
Save up to $200! Final Agenda Register by February 23 COVER CHI’s 13th Annual CONFERENCE AT-A-GLANCE PLENARY KEYNOTES SHORT COURSES Drug Discovery AGENDA Plenary April 3-4 Conferences »» Protein-Protein Interactions Keynotes »» Inflammation»&»Autoimmune» Inhibitors Chemistry »» Kinase»Inhibitor»Chemistry Optimizing Small Molecules for Tomorrow's Therapeutics »» GPCR-Targeted Drug Design »» Fragment-Based»Drug» Activity-Based April 2-6, 2018 | San Diego, CA | Hilton San Diego Bayfront Discovery Proteomics: April 4-5 Conferences Protein and »» Ubiquitin»Proteasome»System» Ligand Discovery Inhibitors on a Global Scale CONFERENCE PROGRAMS »» Small»Molecules»for»Cancer» Benjamin F. Cravatt, Immunotherapy PhD, Professor and APRIL 3-4 APRIL 4-5 APRIL 6 Co-Chair, Department »» Macrocyclics»&»Constrained» of Molecular Peptides Medicine, The Protein-Protein Ubiquitin Proteasome Biophysical Approaches »» Targeting»Complex» Scripps Research Membrane»Proteins Institute Interactions System Inhibitors for Drug Discovery April 6 Symposia »» Biophysical»Approaches»for» Lead Optimization Inflammation & Small Molecules for Drug»Discovery for Drug Metabolism Autoimmune Inhibitors Cancer Immunotherapy »» Lead»Optimization»for»Drug» & Safety Metabolism»&»Safety » Targeting Ras » Blood-Brain»Penetrant» Kinase Inhibitor Macrocyclics & Blood-Brain Inhibitors and MYC for the Treatment of Chemistry Constrained Peptides Penetrant Inhibitors HOTEL & TRAVEL Cancer Stephen Fesik, SPONSORSHIP PhD, Professor GCPR-Targeted Targeting Complex Plus Short Courses & EXHIBIT of Biochemistry, Drug Design Membrane Proteins on April 2 & April 4 Pharmacology, and REGISTRATION Chemistry, Orrin H. Ingram II Chair in Cancer Research, Fragment-Based Click Here to register Online Vanderbilt University Drug Discovery DrugDiscoveryChemistry.com School of Medicine DrugDiscoveryChemistry.com Premier Sponsors: A Division of Cambridge Innovation Institute Save up to $200! Register by February 23 COVER CONFERENCE AT-A-GLANCE CONFERENCE AT-A-GLANCE PLENARY KEYNOTES SHORT COURSES AGENDA Monday Tuesday Wednesday Thursday Friday April 3-4 Conferences APRIL 2 APRIL 3 APRIL 4 APRIL 5 APRIL 6 »» Protein-Protein Interactions »» Inflammation»&»Autoimmune» Inhibitors BIOPHYSICAL PRE-CONFERENCE PROTEIN-PROTEIN COURSES* DINNER SHORT UBIQUITIN PROTEASOME » APPROACHES FOR » Kinase»Inhibitor»Chemistry SHORT COURSES* INTERACTIONS SYSTEM INHIBITORS »» GPCR-Targeted Drug Design DRUG DISCOVERY »» Fragment-Based»Drug» Discovery LEAD OPTIMIZATION INFLAMMATION & SMALL MOLECULES FOR April 4-5 Conferences FOR DRUG AUTOIMMUNE INHIBITORS CANCER IMMUNOTHERAPY »» Ubiquitin»Proteasome»System» METABOLISM & SAFETY Inhibitors »» Small»Molecules»for»Cancer» Immunotherapy KINASE INHIBITOR MACROCYCLICS & BLOOD-BRAIN »» Macrocyclics»&»Constrained» CHEMISTRY CONSTRAINED PEPTIDES PENETRANT INHIBITORS Peptides »» Targeting»Complex» Membrane»Proteins *Separate registration is required April 6 Symposia GCPR-TARGETED TARGETING COMPLEX »» Biophysical»Approaches»for» DRUG DESIGN MEMBRANE PROTEINS Drug»Discovery »» Lead»Optimization»for»Drug» Metabolism»&»Safety »» Blood-Brain»Penetrant» FRAGMENT-BASED Inhibitors DRUG DISCOVERY TRACK-HOPPING Attendees at Drug Discovery Chemistry are HOTEL & TRAVEL encouraged to “track-hop” between concurrent : Though you register for a particular SPONSORSHIP sessions conference or symposium, in reality you gain access to all & EXHIBIT concurrent conferences or symposia. For the best value, REGISTRATION register for a Premium Package, and gain access to all 12 conferences/symposia, plus two short courses, over five days of programming that best fits your research needs. Click Here to register Online DrugDiscoveryChemistry.com A Division of Cambridge Innovation Institute DrugDiscoveryChemistry.com • 2 Save up to $200! Register by February 23 COVER SPONSORS CONFERENCE AT-A-GLANCE PLENARY KEYNOTES PREMIER SPONSORS: SHORT COURSES AGENDA April 3-4 Conferences »» Protein-Protein Interactions »» Inflammation»&»Autoimmune» Inhibitors »» Kinase»Inhibitor»Chemistry »» GPCR-Targeted Drug Design »» Fragment-Based»Drug» Discovery April 4-5 Conferences CORPORATE SPONSORS: »» Ubiquitin»Proteasome»System» Inhibitors »» Small»Molecules»for»Cancer» Immunotherapy »» Macrocyclics»&»Constrained» Peptides »» Targeting»Complex» Membrane»Proteins April 6 Symposia »» Biophysical»Approaches»for» Drug»Discovery »» Lead»Optimization»for»Drug» Metabolism»&»Safety »» Blood-Brain»Penetrant» Inhibitors HOTEL & TRAVEL SPONSORSHIP & EXHIBIT REGISTRATION CORPORATE SUPPORT SPONSORS: Click Here to register Online DrugDiscoveryChemistry.com A Division of Cambridge Innovation Institute DrugDiscoveryChemistry.com • 3 Save up to $200! Register by February 23 PLENARY KEYNOTES COVER CONFERENCE AT-A-GLANCE PLENARY KEYNOTES April 3, 2018 | 4:40 pm April 5, 2018 | 8:55 am SHORT COURSES Activity-Based Proteomics: Protein and Targeting Ras and MYC for AGENDA Ligand Discovery on a Global Scale the Treatment of Cancer April 3-4 Conferences Benjamin F. Cravatt, PhD Stephen Fesik, PhD »» Protein-Protein Interactions Professor and Co-Chair, Department of Molecular Medicine, The Scripps Professor of Biochemistry, Pharmacology, and Chemistry, Orrin H. Ingram II »» Inflammation»&»Autoimmune» Research Institute Chair in Cancer Research, Vanderbilt University School of Medicine Inhibitors »» Kinase»Inhibitor»Chemistry Dr. Cravatt is a Professor and Co-Chair of the Department of Dr. Fesik’s research focus is on cancer drug discovery using »» GPCR-Targeted Drug Design Molecular Medicine at The Scripps Research Institute. His fragment-based approaches and structure-based drug »» Fragment-Based»Drug» research group is interested in understanding the roles that design. Prior to joining Vanderbilt in May 2009, Dr. Fesik was Discovery enzymes play in physiological and pathological processes, the Divisional Vice President of Cancer Research at Abbott April 4-5 Conferences especially as pertains to the nervous system and cancer. Dr. (2000-2009) where he built a pipeline of compounds that »» Ubiquitin»Proteasome»System» Inhibitors Cravatt obtained his undergraduate education at Stanford are showing promising anti-cancer activities in early stage »» Small»Molecules»for»Cancer» University, receiving a BS in the Biological Sciences and a BA clinical trials. While at Abbott, he also developed a few new Immunotherapy in History. He then received a PhD from The Scripps Research NMR methods, determined the three-dimensional structures »» Macrocyclics»&»Constrained» Institute (TSRI) in 1996. Professor Cravatt joined the faculty at of several proteins and protein/ligand complexes, pioneered Peptides »» Targeting»Complex» TSRI in 1997. Dr. Cravatt is a co-founder and scientific advisor a method for drug discovery called SAR by NMR, and applied Membrane»Proteins of Activx Biosciences, Abide Therapeutics, and Vividion this method to identify and optimize ligands for binding to April 6 Symposia Therapeutics. His honors include a Searle Scholar Award, the many protein drug targets. His research has also involved the »» Biophysical»Approaches»for» Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, use of siRNA for target identification and target validation. Drug»Discovery the Protein Society Irving Sigal Young Investigator Award, Dr. Fesik has published more than 240 papers, trained »» Lead»Optimization»for»Drug» Metabolism»&»Safety the Tetrahedron Young Investigator Award in Bioorganic 38 postdoctoral fellows, has been a reviewer for several »» Blood-Brain»Penetrant» and Medicinal Chemistry, the ASBMB Merck Award, and government funding agencies and has served as a member Inhibitors memberships in the National Academy of Sciences and of the Editorial Boards of many peer-reviewed journals. He HOTEL & TRAVEL American Academy of Arts and Sciences. is currently a member of Aileron Therapeutics SAB and the Bruker Board of Directors. His three awards from Abbott SPONSORSHIP & EXHIBIT include Researcher of the Year Team Award (2008). He has also received the NIH Director's Pioneer Award (2010), and REGISTRATION honors from numerous academic societies, the most recent being the AACR Award for Outstanding Achievement in Click Here to register Online Chemistry in Cancer Research (2012). DrugDiscoveryChemistry.com A Division of Cambridge Innovation Institute DrugDiscoveryChemistry.com • 4 Save up to $200! Register by February 23 APRIL 2ND & 4TH * COVER Short Courses CONFERENCE AT-A-GLANCE Afternoon Short Courses SC4: Diversity-Oriented Platforms for SC7: Introduction to Targeted Covalent Inhibitors Ligand Discovery Instructor: Mark Schnute, PhD, Associate Research PLENARY KEYNOTES Monday, april 2, 2:00 - 5:00 pM Instructors: Sepideh Afshar, PhD, Principal Research Fellow, Biotherapeutics Chemistry & Immunoscience SHORT COURSES Scientist, Department of Protein Engineering, Eli Lilly Research, Pfizer Global R&D SC1: Ligand-Receptor Molecular Interactions and Company • Overview of covalent drugs, irreversible AGENDA and Drug Design Svetlana Belyanskaya, PhD, Encoded Library and reversible inhibitors including recent Instructor: Maricel Torrent, PhD, Senior Scientist, AbbVie Technologies, R&D Platform Technology & Science, clinical examples April 3-4 Conferences • Drug design principles generally applicable to all GSK Boston • Biochemical analysis of covalent inhibitors »» Protein-Protein Interactions medicinal chemistry programs Pros and cons of affinity based screening platforms in • Design considerations for targeted »» Inflammation»&»Autoimmune» • Interpretation